Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kezar Life Sciences (KZR) EPS (Basic) (2021 - 2025)

Historic EPS (Basic) for Kezar Life Sciences (KZR) over the last 5 years, with Q2 2025 value amounting to -$1.87.

  • Kezar Life Sciences' EPS (Basic) rose 3682.43% to -$1.87 in Q2 2025 from the same period last year, while for Sep 2025 it was -$6.89, marking a year-over-year increase of 4749.04%. This contributed to the annual value of -$11.49 for FY2024, which is 1819.06% up from last year.
  • As of Q2 2025, Kezar Life Sciences' EPS (Basic) stood at -$1.87, which was up 3682.43% from -$2.27 recorded in Q1 2025.
  • Kezar Life Sciences' 5-year EPS (Basic) high stood at -$0.25 for Q2 2021, and its period low was -$9.37 during Q4 2022.
  • Its 5-year average for EPS (Basic) is -$2.05, with a median of -$1.87 in 2025.
  • Its EPS (Basic) has fluctuated over the past 5 years, first plummeted by 350384.62% in 2022, then skyrocketed by 5261.47% in 2023.
  • Quarter analysis of 5 years shows Kezar Life Sciences' EPS (Basic) stood at -$0.26 in 2021, then crashed by 3503.85% to -$9.37 in 2022, then surged by 52.61% to -$4.44 in 2023, then soared by 37.54% to -$2.77 in 2024, then skyrocketed by 32.57% to -$1.87 in 2025.
  • Its EPS (Basic) stands at -$1.87 for Q2 2025, versus -$2.27 for Q1 2025 and -$2.77 for Q4 2024.